Storia in 4 fonti

Dhoot Transmission, Molbio Diagnostics IPOs see over 70 times subscription on closing day

Dhoot Transmission and Molbio Diagnostics IPOs saw over 70 times subscription, showcasing strong investor demand on closing day.

Raccontata da

economictimes.indiatimes.com

thehindubusinessline.com

m.economictimes.com

newsbytesapp.com

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

thehindubusinessline.comStai leggendo2 g fa

Dhoot Transmission, Molbio Diagnostics IPOs see over 70 times subscription on closing day

Two Indian IPOs—Dhoot Transmission (₹3K cr) and Molbio Diagnostics—oversubscribed 74x and 70x; QIB demand >180x. Anchor backing (Bain, Temasek, BlackRock) signals India supply-chain and healthcare infrastructure confidence—strategic for enterprise tech stack planning.

originale

Timeline cronologica

lunedì 10 agosto 2026·economictimes.indiatimes.com
Can Molbio Diagnostics IPO deliver long-term growth for high risk investors?
Molbio Diagnostics aims to secure ₹200 crore to enhance its capital expenditures through a new issuance of shares. In tandem, the firm intends to reduce promoter stake by…
lunedì 10 agosto 2026·thehindubusinessline.com
Dhoot Transmissions IPO opens today: Should you subscribe at ₹829-871? What brokerages say
Dhoot Transmissions IPO opens today at ₹829-871, backed by Bain Capital, attracting significant investor interest and promising long-term growth.

Dhoot Transmission, Molbio Diagnostics IPOs see over 70 times subscription on closing day

Confronto fonti

Dhoot Transmission, Molbio Diagnostics IPOs see over 70 times subscription on closing day

Timeline cronologica

Can Molbio Diagnostics IPO deliver long-term growth for high risk investors?

Dhoot Transmissions IPO opens today: Should you subscribe at ₹829-871? What brokerages say

Dhoot Transmission IPO Day 3: GMP signals strong 29% listing gain. What are analysts saying?

Dhoot Transmission's Rs 3,067 crore IPO opens for subscription; GMP signals 30% listing gains. Should you bid?

Dhoot Transmission IPO: Does 30% GMP make it a buy?

Molbio Diagnostics IPO: Analyst recommendations—should you subscribe or give it a miss?

Dhoot Transmission IPO opens today; GMP signals 30% listing gains — Should you subscribe?

Dhoot Transmission's Rs 3,067 crore IPO opens for subscription; GMP signals 30% listing gains. Should you bid?

Molbio Diagnostics IPO opens: Should you subscribe for Rs 940 crore issue?

Dhoot Transmission IPO subscribed 36% so far on day 1, brokerages largely bullish

Dhoot Transmission IPO Day 2; GMP signals 30% listing gain - Should you subscribe?

Molbio IPO Day 2: GMP hits at 17% listing gains. Should you bid?

Dhoot, Milky Mist or Molbio? What should investors pick in Rs 7,000 crore IPO rush this week

Dhoot Transmission IPO: Does 30% GMP make it a buy?

Molbio Diagnostics IPO Day 3: GMP hints at 17% listing gain, issue booked nearly 5x. Should you participate?

Dhoot Transmission IPO Day 3: GMP signals strong 29% listing gain. What are analysts saying?

Dhoot Transmission, Molbio Diagnostics IPOs see over 70 times subscription on closing day

Dhoot Transmission allotment likely today; GMP hints at strong listing: Here's how to check your status

Molbio Diagnostics IPO allotment likely today; GMP at 20% — Here’s how to check status